Dr. Peter Forsyth and Dr. Lilit Karapetyan were awarded the R01 grant by NIH
An R01 grant is a prestigious NIH research project grant supporting mature, hypothesis-driven studies with solid preliminary data. Typically providing up to five years of funding, R01s allow budgets that align with project needs, often between $250,000 to $500,000 annually, though complex projects may request more. These grants cover costs for personnel, materials, equipment, and other essentials needed to conduct research. The application process is highly competitive, ensuring selected projects offer strong potential for scientific impact.
This funding supports various aspects of research, including personnel, supplies, equipment, and facility fees, as well as data analysis, participant recruitment, and dissemination of results. The flexibility of R01 grants also allows researchers to adapt to unexpected challenges and modify methodologies if needed, as long as the project remains aligned with the initial objectives and approved budget.
Dr. Peter Forsyth, Chairman of the Neuro-Oncology Program at Moffitt Cancer Center and Professor of Oncology at the University of South Florida, received a significant FBRP/Bankhead-Coley grant, marking his first R01-equivalent award. His research project, “Using Dendritic Cell Therapy to Enhance the Adaptive Immune Response in Leptomeningeal Disease from Breast Cancer as an Effective Treatment and Prevention against LMD Recurrence,” explores the potential of dendritic cell therapy to strengthen immune defenses against leptomeningeal disease (LMD) in breast cancer patients. This innovative approach aims to prevent LMD recurrence, potentially transforming treatment outcomes for this challenging condition.
Dr. Lilit Karapetyan, Assistant Member in the Department of Cutaneous Oncology, Immuno-oncology program as well as an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine, received a prestigious US Army/CDMRP grant, marking her first R01-equivalent award. Her research, “Evaluating B-T Cell Crosstalk within Tertiary Lymphoid Structures in Melanoma Progression and Immune Checkpoint Blockade,” investigates the role of B and T cell interactions in melanoma. This study aims to uncover how these immune cell dynamics within tertiary lymphoid structures influence tumor progression and the effectiveness of immune checkpoint therapies, potentially advancing strategies in melanoma treatment.
For more information visit oncodaily.com
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023